Cargando…

Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review

Patient: Male, 49-year-old Final Diagnosis: Colorectal cancer Symptoms: Hemiparesis • unconsciousness Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual clinical course BACKGROUND: Chemotherapy based on 5-fluorouracil (5-FU) is a well-established treatment for solid cancers, including meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuwono, Kurniawan Agung, Hutajulu, Susanna Hilda, Gofir, Abdul, Nugroho, Dhite Bayu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083054/
https://www.ncbi.nlm.nih.gov/pubmed/37012696
http://dx.doi.org/10.12659/AJCR.938437
_version_ 1785021428142178304
author Yuwono, Kurniawan Agung
Hutajulu, Susanna Hilda
Gofir, Abdul
Nugroho, Dhite Bayu
author_facet Yuwono, Kurniawan Agung
Hutajulu, Susanna Hilda
Gofir, Abdul
Nugroho, Dhite Bayu
author_sort Yuwono, Kurniawan Agung
collection PubMed
description Patient: Male, 49-year-old Final Diagnosis: Colorectal cancer Symptoms: Hemiparesis • unconsciousness Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual clinical course BACKGROUND: Chemotherapy based on 5-fluorouracil (5-FU) is a well-established treatment for solid cancers, including metastatic or advanced colon cancer. Despite its efficacy, 5-FU can cause rare but serious adverse events such as acute neurotoxicity, which presents as symptoms similar to stroke. CASE REPORT: We report the case of a patient who was diagnosed with stage IV colorectal cancer and who underwent chemotherapy with a high dose of 5-FU as part of the FOLFIRI (Folinic Acid, Fluorouracil, Irinotecan) treatment plan. During the seventh, eighth, and ninth cycles of chemotherapy, the patient suffered from severe encephalopathy, and the cause of this condition was determined to the 46-hour continuous intravenous infusion of 5-FU, which was part of the FOLFIRI regimen. CONCLUSIONS: 5-FU-induced hyperammonemic encephalopathy is a rare but serious adverse event that requires immediate recognition and treatment. The first step in managing this condition is to halt the 5-FU infusion and provide the patient with high volumes of fluid. Although most cases of 5-FU-induced encephalopathy resolve spontaneously, recurrence is possible if the drug is re-administered to the same patient. Therefore, it is crucial for healthcare providers to closely monitor patients receiving 5-FU chemotherapy and be aware of the signs and symptoms of hyperammonemic encephalopathy. Early intervention can prevent further complications and ensure the best possible outcome for the patient. It is important to note that while 5-FU-induced hyperammonemic encephalopathy is rare, it highlights the importance of closely monitoring patients receiving chemotherapy to identify and treat adverse events promptly. This can help improve patient outcomes and prevent serious long-term complications.
format Online
Article
Text
id pubmed-10083054
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-100830542023-04-10 Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review Yuwono, Kurniawan Agung Hutajulu, Susanna Hilda Gofir, Abdul Nugroho, Dhite Bayu Am J Case Rep Articles Patient: Male, 49-year-old Final Diagnosis: Colorectal cancer Symptoms: Hemiparesis • unconsciousness Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual clinical course BACKGROUND: Chemotherapy based on 5-fluorouracil (5-FU) is a well-established treatment for solid cancers, including metastatic or advanced colon cancer. Despite its efficacy, 5-FU can cause rare but serious adverse events such as acute neurotoxicity, which presents as symptoms similar to stroke. CASE REPORT: We report the case of a patient who was diagnosed with stage IV colorectal cancer and who underwent chemotherapy with a high dose of 5-FU as part of the FOLFIRI (Folinic Acid, Fluorouracil, Irinotecan) treatment plan. During the seventh, eighth, and ninth cycles of chemotherapy, the patient suffered from severe encephalopathy, and the cause of this condition was determined to the 46-hour continuous intravenous infusion of 5-FU, which was part of the FOLFIRI regimen. CONCLUSIONS: 5-FU-induced hyperammonemic encephalopathy is a rare but serious adverse event that requires immediate recognition and treatment. The first step in managing this condition is to halt the 5-FU infusion and provide the patient with high volumes of fluid. Although most cases of 5-FU-induced encephalopathy resolve spontaneously, recurrence is possible if the drug is re-administered to the same patient. Therefore, it is crucial for healthcare providers to closely monitor patients receiving 5-FU chemotherapy and be aware of the signs and symptoms of hyperammonemic encephalopathy. Early intervention can prevent further complications and ensure the best possible outcome for the patient. It is important to note that while 5-FU-induced hyperammonemic encephalopathy is rare, it highlights the importance of closely monitoring patients receiving chemotherapy to identify and treat adverse events promptly. This can help improve patient outcomes and prevent serious long-term complications. International Scientific Literature, Inc. 2023-04-04 /pmc/articles/PMC10083054/ /pubmed/37012696 http://dx.doi.org/10.12659/AJCR.938437 Text en © Am J Case Rep, 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Yuwono, Kurniawan Agung
Hutajulu, Susanna Hilda
Gofir, Abdul
Nugroho, Dhite Bayu
Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
title Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
title_full Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
title_fullStr Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
title_full_unstemmed Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
title_short Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
title_sort recurrent reversible stroke-like encephalopathy after 5-fluorouracil (5-fu) chemotherapy: a case report and literature review
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083054/
https://www.ncbi.nlm.nih.gov/pubmed/37012696
http://dx.doi.org/10.12659/AJCR.938437
work_keys_str_mv AT yuwonokurniawanagung recurrentreversiblestrokelikeencephalopathyafter5fluorouracil5fuchemotherapyacasereportandliteraturereview
AT hutajulususannahilda recurrentreversiblestrokelikeencephalopathyafter5fluorouracil5fuchemotherapyacasereportandliteraturereview
AT gofirabdul recurrentreversiblestrokelikeencephalopathyafter5fluorouracil5fuchemotherapyacasereportandliteraturereview
AT nugrohodhitebayu recurrentreversiblestrokelikeencephalopathyafter5fluorouracil5fuchemotherapyacasereportandliteraturereview